Scientists Link a DNA-Building Enzyme to Fat Rewiring and Chemotherapy Failure in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains one of the most lethal human cancers, and one of the central reasons is that its tumors frequently shrug off gemcitabine, the nucleoside-analog chemotherapy that has anchored treatment for decades. A new study published in BMC Cancer by Na Song, Yue Wu, Yongcan Wu, Xuekuan Huang, Jianwei Wang and colleagues now adds an intriguing piece to the puzzle of why that happens. The research identifies ribonucleotide reductase regulatory subunit M2, better known as RRM2, as a gene that appears to sit at the junction of two processes long thought to operate largely in parallel: the supply of DNA building blocks that gemcitabine is designed to sabotage, and the wholesale remodeling of fat metabolism that pancreatic tumors use to survive in a hostile environment.

RRM2 is not an unfamiliar name in oncology. As the regulatory subunit of ribonucleotide reductase, the enzyme complex that converts ribonucleotides into the deoxyribonucleotides needed for DNA synthesis and repair, it is essential for proliferating cells and has previously been associated with aggressive disease in several tumor types. What makes the new work distinctive is its attempt to connect RRM2 to lipid biology and to chemotherapy response within the same framework, using a combination of bulk transcriptomic data, clinical survival information, single-cell RNA sequencing, tissue-level protein evidence, and a battery of laboratory experiments in pancreatic cancer cell lines and mouse models.

The bioinformatic arm of the study established the clinical backdrop. RRM2 was found to be upregulated in pancreatic ductal adenocarcinoma compared with non-tumor tissue, and elevated expression tracked with unfavorable clinical characteristics and shorter overall survival. When the researchers examined the molecular programs that RRM2 expression correlated with, they found a signature that went well beyond simple proliferation. RRM2 levels were associated with hypoxia, epithelial-mesenchymal transition, and, notably, fatty-acid-metabolism-related programs, with correlations to genes such as FASN, the enzyme that manufactures fatty acids from scratch; ACSL4, which activates fatty acids for further metabolism; PLIN2, a marker of lipid droplets; SCD, which desaturates fatty acids; and SREBF1, the master transcription factor controlling the lipogenic program.

That correlation set the stage for the study’s central experiment. The team exposed PANC-1 and SW1990 pancreatic cancer cells to palmitate, a saturated fatty acid, to mimic the lipid-rich conditions that pancreatic tumors often encounter, and then tested how the cells responded to gemcitabine. The result was striking: palmitate exposure increased the IC50 value of gemcitabine, meaning that substantially more drug was required to achieve the same killing effect. Under these lipid-stressed conditions, the cells adopted a recognizable phenotype characterized by high RRM2, high thymidylate synthase (TYMS), low DCK, the enzyme that activates gemcitabine inside the cell, high FASN, high ACSL4, and elevated PCNA, a proliferation marker. Lipid-droplet accumulation, visualized with BODIPY 493/503 staining, accompanied this shift.

To test whether RRM2 was merely a passenger or an active participant in this drug-tolerant state, the researchers depleted it using small interfering RNA. The consequences were broad. RRM2 knockdown reduced the gemcitabine IC50, meaning the cells became more sensitive to the drug. It also suppressed lipid accumulation and proliferative markers, and, importantly, restored expression of DCK, the very enzyme that pancreatic tumors often lose to deactivate gemcitabine. At the same time, the treated cells accumulated more γ-H2AX, a molecular beacon for DNA double-strand breaks, and showed increased apoptosis. When the team re-expressed RRM2 in the depleted cells, these effects were partially reversed, supporting a causal role for the gene rather than an off-target artifact of the knockdown procedure.

The study then probed the mechanism linking RRM2 to fat metabolism. Because RRM2 is a nucleotide-metabolism protein, it cannot directly regulate lipid genes in the way a transcription factor would, so the investigators turned to SREBF1, the gene encoding SREBP1, the transcriptional regulator of fatty-acid synthesis. In a series of reciprocal experiments, they showed that re-expressing SREBF1 in RRM2-depleted cells partially restored lipid accumulation, FASN expression, nuclear SREBP1 protein, and tolerance to gemcitabine. In other words, the lipogenic arm of the phenotype could be rescued independently of RRM2 itself, suggesting that RRM2 and the SREBP1/FASN axis functionally cooperate to produce the gemcitabine-tolerant state rather than one simply causing the other in a linear chain.

Supportive evidence came from an in vivo model using mice fed a high-fat diet, designed to reproduce the metabolic context in which many patients with pancreatic cancer live. In these animals, the high-fat diet attenuated the antitumor activity of gemcitabine, echoing the in vitro finding that lipid abundance blunts drug efficacy. Adding RRM2-targeting siRNA to the high-fat diet plus gemcitabine regimen further reduced xenograft growth and lowered expression of FASN, TYMS, and the proliferation marker Ki-67, while increasing tumor necrosis and γ-H2AX accumulation. The authors are careful to characterize this as supportive rather than definitive evidence of therapeutic benefit, an appropriate level of caution for a xenograft experiment that has not yet been replicated in more faithful models or in patients.

The significance of the work lies in how it reframes gemcitabine resistance. Classic explanations have centered on the drug’s own pathway: insufficient uptake, reduced activation by DCK, accelerated catabolism, or elevated RRM2 itself, which allows cells to out-replicate the drug’s damage by maintaining deoxyribonucleotide pools. The new study does not overturn that framework but widens it, proposing that metabolic adaptation, specifically the SREBP1/FASN-driven accumulation of lipid droplets, operates in concert with nucleotide-metabolism changes to create a state in which the tumor is simultaneously better at copying its DNA and better insulated from metabolic stress. A cell in that state is harder to kill with a drug that works by masquerading as a DNA building block.

There are also translational implications, though they come with caveats. If RRM2 depletion genuinely sensitizes tumors to gemcitabine under lipid-rich conditions, then RRM2 inhibitors, some of which have been explored clinically, or dietary and pharmacological interventions that limit lipid availability could theoretically improve chemotherapy response. The study’s own data temper such optimism: the SREBF1 rescue was partial, the in vivo combination experiment was supportive rather than definitive, and the gap between xenografts and human disease in pancreatic cancer is notoriously wide. Single-agent strategies targeting RRM2 have historically struggled with toxicity, because normal proliferating tissues also depend on ribonucleotide reductase.

What the study does provide is a well-integrated map of a phenomenon that clinicians observe daily: patients with pancreatic cancer respond variably to gemcitabine, and metabolic context appears to matter. By tying RRM2 expression to survival, to lipid-metabolism gene programs, and to measurable changes in drug sensitivity, DNA damage, and apoptosis in controlled experiments, the Chongqing-based team has generated a testable hypothesis about how tumor metabolism and chemotherapy resistance interlock. The next steps, validating the RRM2–SREBP1/FASN axis in patient-derived models and determining whether disrupting lipid remodeling can restore gemcitabine efficacy in the clinic, will determine whether this bioinformatic lead matures into a genuine therapeutic strategy for one of medicine’s most stubborn cancers.

Subject of Research: The role of RRM2 in linking lipid metabolic remodeling and gemcitabine resistance in pancreatic ductal adenocarcinoma

Article Title: Integrated bioinformatics identifies RRM2 as a lipid remodeling- and gemcitabine response-related gene in pancreatic cancer

Article References: Song, N., Wu, Y., Wu, Y., Huang, X., & Wang, J. (2026). Integrated bioinformatics identifies RRM2 as a lipid remodeling- and gemcitabine response-related gene in pancreatic cancer. BMC Cancer. https://doi.org/10.1186/s12885-026-16948-6

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16948-6

Keywords: pancreatic cancer, RRM2, gemcitabine resistance, lipid metabolism, SREBF1, FASN, nucleotide metabolism, chemotherapy resistance, bioinformatics, fatty acid synthesis, apoptosis, BMC Cancer